Literature DB >> 27918638

Small Molecule Microarray Based Discovery of PARP14 Inhibitors.

Bo Peng1, Ann-Gerd Thorsell2, Tobias Karlberg2, Herwig Schüler2, Shao Q Yao1.   

Abstract

Poly(ADP-ribose) polymerases (PARPs) are key enzymes in a variety of cellular processes. Most small-molecule PARP inhibitors developed to date have been against PARP1, and suffer from poor selectivity. PARP14 has recently emerged as a potential therapeutic target, but its inhibitor development has trailed behind. Herein, we describe a small molecule microarray-based strategy for high-throughput synthesis, screening of >1000 potential bidentate inhibitors of PARPs, and the successful discovery of a potent PARP14 inhibitor H10 with >20-fold selectivity over PARP1. Co-crystallization of the PARP14/H10 complex indicated H10 bound to both the nicotinamide and the adenine subsites. Further structure-activity relationship studies identified important binding elements in the adenine subsite. In tumor cells, H10 was able to chemically knockdown endogenous PARP14 activities.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  PARP inhibitors; X-ray crystallography; click chemistry; high-throughput screening; microarrays

Mesh:

Substances:

Year:  2016        PMID: 27918638     DOI: 10.1002/anie.201609655

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  10 in total

Review 1.  Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.

Authors:  Maria Giulia Nizi; Mirko M Maksimainen; Lari Lehtiö; Oriana Tabarrini
Journal:  J Med Chem       Date:  2022-05-24       Impact factor: 8.039

2.  A macrodomain-linked immunosorbent assay (MLISA) for mono-ADP-ribosyltransferases.

Authors:  Jingwen Chen; Albert T Lam; Yong Zhang
Journal:  Anal Biochem       Date:  2017-12-13       Impact factor: 3.365

3.  PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery.

Authors:  Ying Tang; Jinchang Liu; Yu Wang; Li Yang; Bing Han; Yuan Zhang; Ying Bai; Ling Shen; Mingyue Li; Teng Jiang; Qingqing Ye; Xiaoyu Yu; Rongrong Huang; Zhao Zhang; Yungen Xu; Honghong Yao
Journal:  Autophagy       Date:  2020-12-15       Impact factor: 16.016

4.  Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity.

Authors:  Juanjuan Wang; Chenggang Zhu; Dan Song; Ruiqi Xia; Wenbo Yu; Yongjun Dang; Yiyan Fei; Long Yu; Jiaxue Wu
Journal:  Cell Death Discov       Date:  2017-07-10

5.  Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes.

Authors:  Tim J Wigle; W David Church; Christina R Majer; Kerren K Swinger; Demet Aybar; Laurie B Schenkel; Melissa M Vasbinder; Arne Brendes; Claudia Beck; Martin Prahm; Dennis Wegener; Paul Chang; Kevin W Kuntz
Journal:  SLAS Discov       Date:  2019-12-19       Impact factor: 3.341

Review 6.  Mono(ADP-ribosyl)ation Enzymes and NAD+ Metabolism: A Focus on Diseases and Therapeutic Perspectives.

Authors:  Palmiro Poltronieri; Angela Celetti; Luca Palazzo
Journal:  Cells       Date:  2021-01-11       Impact factor: 6.600

7.  The potential association between PARP14 and the SARS-CoV-2 infection (COVID-19).

Authors:  Amanda L Tauber; Stephanie S Schweiker; Stephan M Levonis
Journal:  Future Med Chem       Date:  2021-01-20       Impact factor: 3.808

Review 8.  Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy.

Authors:  Rongyan Zhao; Jiahui Fu; Lingjuan Zhu; Yi Chen; Bo Liu
Journal:  J Hematol Oncol       Date:  2022-02-05       Impact factor: 17.388

Review 9.  Targeting RNA structures with small molecules.

Authors:  Jessica L Childs-Disney; Xueyi Yang; Quentin M R Gibaut; Yuquan Tong; Robert T Batey; Matthew D Disney
Journal:  Nat Rev Drug Discov       Date:  2022-08-08       Impact factor: 112.288

10.  The KU-PARP14 axis differentially regulates DNA resection at stalled replication forks by MRE11 and EXO1.

Authors:  Ashna Dhoonmoon; Claudia M Nicolae; George-Lucian Moldovan
Journal:  Nat Commun       Date:  2022-08-27       Impact factor: 17.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.